Literature DB >> 8332256

Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram.

G Chinaglia1, B Landwehrmeyer, A Probst, J M Palacios.   

Abstract

Receptor autoradiography with [3H]citalopram as ligand was used to study the distribution of serotonin uptake binding sites in post mortem brain tissues from patients with Parkinson's disease, progressive supranuclear palsy and from age-matched controls. Significant decreases in [3H]citalopram binding sites were found in the cerebral cortex of patients with Parkinson's disease and progressive supranuclear palsy. Densities of [3H]citalopram binding sites were significantly reduced in all components of the basal ganglia of Parkinson's disease but only in the head of caudate nucleus of progressive supranuclear palsy patients. The density of [3H]citalopram binding sites in the raphe nuclei of Parkinson's disease was comparable to control values. Our results suggest that serotoninergic terminals are differentially affected in Parkinson's disease and in progressive supranuclear palsy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8332256     DOI: 10.1016/0306-4522(93)90240-g

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  20 in total

1.  The state of the serotonin transporter protein in the platelets of patients with somatoform [correction of somatiform] disorders.

Authors:  A R Belous; S Ramamoorthy; R D Blakely; M I Factor; A M Dupin; A B Katasonov; R H Lozier; A G Beniashvili; M A Morozova; O S Brusov
Journal:  Neurosci Behav Physiol       Date:  2001 Mar-Apr

Review 2.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

4.  Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders.

Authors:  R P Iacono; S M Kuniyoshi; J R Ahlman; G J Zimmerman; G Maeda; R D Pearlstein
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  MPTP-induced executive dysfunction is associated with altered prefrontal serotonergic function.

Authors:  Panchanan Maiti; Laura C Gregg; Michael P McDonald
Journal:  Behav Brain Res       Date:  2015-09-21       Impact factor: 3.332

6.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

7.  Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain.

Authors:  Katarina Varnäs; Christer Halldin; Håkan Hall
Journal:  Hum Brain Mapp       Date:  2004-07       Impact factor: 5.038

8.  Comparison of [123I]beta-CIT and [123I]IPCIT as single-photon emission tomography radiotracers for the dopamine transporter in nonhuman primates.

Authors:  B E Scanley; M S al-Tikriti; M S Gandelman; M Laruelle; Y Zea-Ponce; R M Baldwin; S S Zoghbi; P B Hoffer; D S Charney; S Wang
Journal:  Eur J Nucl Med       Date:  1995-01

9.  Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography.

Authors:  Madhavi Tripathi; Vijay Dhawan; Shichun Peng; Suman Kushwaha; Amit Batla; Abhinav Jaimini; Maria M D'Souza; Rajnish Sharma; Sanjiv Saw; Anupam Mondal
Journal:  Neuroradiology       Date:  2013-01-13       Impact factor: 2.804

10.  Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation.

Authors:  Tultul Nayyar; Michael Bubser; Marcus C Ferguson; M Diana Neely; J Shawn Goodwin; Thomas J Montine; Ariel Y Deutch; Twum A Ansah
Journal:  Eur J Neurosci       Date:  2009-07       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.